Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems
References
- 1. R. Duncan, Polymer conjugates as anticancer nanomedicines,(2006) 688–701; DOI: 10.1038/Nrc1958.
- 2. M. J. Vicent and R. Duncan, Polymer conjugates: nanosized medicines for treating cancer,.(2006) 39–47; DOI: 10.1016/j.tibtech.2005.11.006.
- 3. R. Haag and F. Kratz, Polymer the rapeutics: concepts and applications,.(2006) 1198–1215; DOI: 10.1002/anie.200502113.
- 4. A. A. Adjei, Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent,(2004) 4276–4280; DOI: 10.1158/1078-0432.CCR-040010.
- 5. R. B. Zhao, N. Diop-Bove, M. Visentin and I. D. Goldman, Mechanisms of membrane transport of folates into cells and across epithelia,.(2011) 177–201; DOI: 10.1146/annurev-nutr-072610-145133.
- 6. J. E. Nutt, A. R. Razak, K. O’Too le, F. Black, A. E. Quinn, A. H. Calvert, E. R. Plummer and J. Lunec, The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy,(2010) 553–560; DOI: 10.1038/sj.bjc.6605501.
- 7. W. H. Schuette, A. Groschel, M. S ebastian, S. Andreas, T. Muller, F. Schneller, S. Guetz, C. Eschbach, S. Bohnet, M. I. Leschinger and M. Reck, A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer,(2013) 215–223; DOI: 10.1016/j.cllc.2012.10.001.
- 8. O. Caffo, L. Fratino, R. Barbieri, A. Perin, T. Martini, T. Sava, R. Segati, E. Vaccher, F. Bernardo Bassan, A. Veccia, G. Pappagallo nad E. Galligioni, Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study,.(2013) 180–186; DOI: 10.1016/j.urolonc.2010.11.012.
- 9. A. A. Adjei, Pharmacology and mechanism of action of pemetrexed,(2004) 51–55; DOI: 10.3816/CLC.2004.s.003.
- 10. R. Budzynska, D. Nevozhay, U. Kanska, M. Jagiello, A. Opolski, J. Wietrzyk and J. Boratynski, Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo,.(2007) 415–421.
- 11. D. Nevozhay, R. Budzynska, U. Kanska, M. Jagiello, M. S. Omar, J. Boratynski and A. Opolski, Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier,.(2006) 1135–1143.
- 12. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment,.(2009) 4647–4656; DOI: 10.1016/j.bmc.2009.04.063.
- 13. T. M. Goszczynski, B. Filip-Psurska, K. Kempinska, J. Wietrzyk and J. Boratynski, Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy,.(2014) 1–8; DOI: 10.1002/prp2.47.
- 14. M. Westphal, M. F. James, S. Kozek-Langenecker, R. Stocker, B. Guidet and H. Van Aken, Hydroxyethyl starches: different products-different effects,(2009) 187–202; DOI: 10.1097/ALN.0b013e3181a7ec82.
- 15. T. Masuko, A. Minami, N. Iwasaki, T. Majima, S. Nishimura and Y. C. Lee, Carbohydrate analysis by a phenol-sulfuric acid method in microplate format,.(2005) 69–72; DOI: 10.1016/j.ab.2004.12.001.
Language: English
Page range: 147 - 153
Accepted on: Sep 17, 2015
Published on: Mar 7, 2016
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2016 Jarosław Ciekot, Tomasz Marek Goszczyński, Janusz Boratyński, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.